ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

About ASN

Jonathan Himmelfarb, MD, FASN, Past President

ASN Biography

Jonathan Himmelfarb, MD, FASN is the Joseph W. Eschbach, MD, Endowed Chair in Kidney Research, Director of the Kidney Research Institute, and Professor of Medicine at the University of Washington.

Dr. Himmelfarb brings a wealth of experience to his service as a council member. He served as first chair of the ASN Public Policy Board from 2006-2009 and was central to developing a stronger voice for ASN in the public health arena and in strengthening and defining the role ASN plays in advocating for constructive change in kidney care policy, research and treatment. Dr. Himmelfarb has also contributed to ASN through his work with the ASN Dialysis Advisory Group, Program Committee, Postgraduate Education Committee, and Board of Advisors. His extensive experience working with other organizations central to kidney care will help ASN maintain and build the external relationships that advance the field of nephrology. Dr. Himmelfarb also possesses significant publications experience, including the Journal of the American Society of Nephrology, NephSAP, Kidney International, and Faculty of 1000 in Medicine, Dialysis and Renal Transplantation.

Dr. Himmelfarb's research interests involve metabolic complications of kidney disease including CKD, ESRD and AKI. In particular, he has focused on understanding how the loss of kidney function contributes to increased oxidative stress, inflammation, insulin resistance and endothelial dysfunction, and ultimately cardiovascular risk in kidney disease. Dr. Himmelfarb has also been involved in creating statewide, community-based research into healthcare disparities related to chronic kidney disease and he evaluates novel approaches to renal replacement therapies.